Main content area

A baru almond–enriched diet reduces abdominal adiposity and improves high-density lipoprotein concentrations: a randomized, placebo-controlled trial

de Souza, Rávila Graziany Machado, Gomes, Aline Corado, de Castro, Inar Alves, Mota, João Felipe
Nutrition 2018 v.55-56 pp. 154-160
abdominal fat, almonds, antioxidants, apolipoproteins, blood pressure, cardiovascular diseases, cholesteryl ester transfer protein, clinical trials, confidence interval, diet, dual-energy X-ray absorptiometry, glucose, high density lipoprotein, lipid composition, obesity, phenolic compounds, polyunsaturated fatty acids, protein content, protein synthesis, risk reduction, waist circumference, women
Nut consumption is associated with reduced risks of cardiovascular disease. Baru almonds have a high protein content and high quantities of mono- and polyunsaturated fatty acids, phenolic compounds, and antioxidants. This study aimed to evaluate the effects of a baru almond–enriched diet on body composition and markers of lipid metabolism in overweight and obese women.A randomized, placebo-controlled, 8-wk clinical trial of 46 overweight and obese women was conducted. Participants were randomly assigned to 1 of 2 normocaloric and isoenergetic diets: baru almond–enriched diet or baru almond–free diet. Both groups received dietary instructions. Body composition was assessed by anthropometry and dual-energy x-ray absorptiometry. Blood pressure, glucose levels, lipid profile, and plasma fatty acids, as well as apolipoproteins, angiopoietin-like-3, and cholesteryl ester transfer protein expression, were determined at the beginning and end of the study.The consumption of baru almonds reduced waist circumference (–2.45 cm; 95% confidence interval [CI], –3.90 to –0.23; P = 0.03), cholesteryl ester transfer protein expression (–0.23 mcg/mL; 95% CI, –1.24 to –0.08; P = 0.03), and increased high-density lipoprotein concentrations (+4.82 mg/dL; 95% CI, 0.03–8.88; P = 0.04) compared with baru almond–free diet.A baru almond–enriched diet for 8-wk reduced abdominal adiposity and improved high-density lipoprotein in overweight and obese women. This trial was registered at as RBR-2 wpryx.